

Latest News

Submit Press Release

PR Home

Latest News

Feeds

Alerts

Submit Free Press Release

Journalist Account

PRNewswire Distribution

Country News

[United States](#)[Australia](#)[India](#)[Hong Kong](#)[United Kingdom](#)

[More Countries](#)

Industry News

All News

Exclusive News

June 2015

Mo Su Sa Fr Th We Tu

15 14 13 12 11 10 9

Nemucore Medical Innovations, Inc. Appoints Daniel E. Geffken as Interim Chief Financial Officer

PRLog - June 15, 2015 - WORCESTER, Mass. -- Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of molecularly targeted therapies to treat multidrug resistant cancers, today announced the appointment of Daniel E. Geffken, M.B.A. as its Interim Chief Financial Officer. "We are thrilled to have Dan join Nemucore's growing team. His extensive financial experience and leadership will greatly benefit Nemucore," said Timothy P. Coleman, President and Chief Executive Officer of Nemucore. "Dan has been the CFO of public and private life sciences companies and has the background to help develop the effective financial strategies to capitalize Nemucore's rapid growth."

Mr. Geffken is a Founder and Managing Director of Danforth Advisors, a consulting firm specializing in providing financial and strategic support to life sciences companies. He brings more than 22 years of experience in the life science industry, ranging from early start-ups to publicly traded companies with \$1 billion+ market capitalizations. Previously, he served as COO or CFO of four publicly traded and four privately held companies and was interim CEO of a medical device company. Daniel has assisted in raising more than \$1 billion in equity and debt securities. He serves on the Board of Directors for Alcobra Ltd., a biopharmaceutical company that completed an initial public offering in May 2013. He has a B.S. in Economics from The Wharton School, University of Pennsylvania and a M.B.A. from Harvard Business School.

About Nemucore Medical Innovations

Nemucore Medical Innovations, Inc. is a privately held biopharmaceutical clinical-stage oncology company developing innovative therapeutics, with a focus on treating multi-drug resistant cancers. Nemucore's most advanced product NMI-900, a "Best-In-Class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late 2015. Two additional therapeutics are anticipated to begin clinical trials in 2016 targeting further oncology indications, including breast cancer. For more information visit our website www.nemucore.com

Forward Looking Statement

This press release makes forward-looking statements regarding future events and our future performance about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's therapeutic programs, the timeline for clinical development and regulatory approval of the Company's compounds, the structure of the Company's planned clinical trials, the Company's rights to develop or commercialize its products, the Company's obligations to make milestone payments and royalties and the ability of the Company to finance contemplated development activities. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "proposed," and other similar expressions generally identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements entail various significant risks and uncertainties that could cause our actual results to differ materially from those expressed in such forward-looking statements. Applicable risks and uncertainties include the risks that the preclinical testing of the Company's compounds may not be predictive of the success of later clinical trials, that the Company may be unable to successfully complete the clinical development of its products, that the development of the Company's products may take longer or cost more than planned, and that the Company's products may not receive regulatory approval or become commercially successful products. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not intend to update any of the information contained in any forward-looking statement, except as required by law. More information about the risks and uncertainties faced by

Similar ?

[Nemucore Medical Innovations, Inc. Appoints Bryan Costantino to Board of Directors](#)

[WPI Grants Provost Award to Student Team for Their Work at Nemucore Medical Innovations](#)

[Nemucore Medical Innovations Presents at 4th Annual CCNE National Cancer Institute Site Visit](#)

[Nemucore Publishes Research Article, "Nanoemulsions in Translational Research"](#)

[Nemucore Medical Innovations Appoints Douglas G. Bailey to Board of Directors](#)

Daily News

[Happy Endings Farms Creates Lasting Memories With A South Florida Send Off](#)

[Ladies Day 'Summer Edition' @ Gary Mathews VW](#)

[Electronics62761 is hiring over 150 personnel in China](#)

[No More Hand Washing Hair extensions](#)

[Soabos Magazine Issue 03 by Timothy Frazier](#)

Weekly News

[ACES modifies May 29, 2015 FOIA/Public Records Request to Stanly County Board of Education - 1373 views](#)

[Country-Pop Canadian Songbird Anne Murray, to be Honored in Streaming Radio Tribute on June 20, 2015 - 991 views](#)

[Venti Group Announces Launch Of The Dual Polarized Low PIM Venti DAS MIMO Antenna In Europe With EAD - 864 views](#)

[Maryland Faerie Festival Announces the 11th Annual Celebration of the Maryland Faerie Festival - 850 views](#)

[ART/PUNK Show Erupts On New York's L.E.S - 676 views](#)

Jun 15, 2015 News

Nemucore Medical Innovations, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Nemucore Medical Innovations, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

--- End ---

[Follow](#) [Email](#) [Embed](#) [PDF / Print](#)



Contact Email : [Contact Author](#) ***@nemucore.com ✓
Source : Nemucore Medical Innovations, Inc.
Location : [Worcester - Massachusetts - United States](#)
Industry : [Biotech, Medical](#)
Tags : [nemucore](#), [nmi](#), [targeted therapeutics](#), [multidrug resistant cancer](#), [nemucore medical innovations](#)
Shortcut : [prlog.org/12465054](#)

Verified Account Email Address ✓
Verified Account Phone Number ✓

Disclaimer: Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others. [Report Abuse](#)

Latest Press Releases By "[Nemucore Medical Innovations](#)"

- [Nemucore Medical Innovations, Inc. Announces Election of Independent Director](#)
- [Nemucore Announces Publication in Pharmaceutical Research](#)
- [Nemucore Announces Publication in Tissue Barriers](#)
- [Nemucore Medical Innovations, Inc. Appoints Bryan Costantino to Board of Directors](#)
- [WPI Grants Provost Award to Student Team for Their Work at Nemucore Medical Innovations](#)

[More...](#)

Trending News...

- [Happy Endings Farms Creates Lasting Memories With A South Florida Send Off](#)
- [Ladies Day 'Summer Edition' @ Gary Mathews VW](#)
- [Go4customer Wins Leading Financial Services Groups AS Business Client](#)
- [Electronics62761 is hiring over 150 personnel in China](#)
- [Local Business, HeartfeltBooks.com Needs Your Vote for \\$100,000 Grant](#)

Is your website open for business?

[SiteMap](#) | [Privacy Policy](#) | [Terms of Service](#) | [Copyright Notice](#) | [About](#) | [Advertise](#)

Like PRLog?

